Strategic partnerships Leverage recent and ongoing collaborations with Parhelia, Hamamatsu, Lunaphore, Nucleai, Scailyte, and Ultivue to position Sirona Dx as a preferred integration partner for spatial biology workflows and multi-omics platforms, unlocking co-selling and joint development opportunities.

Expanded platform reach Promote Sirona Dx as technology agnostic in spatial biology, capable of integrating leading multiplexed imaging platforms and CyTOF, to address pharma clients seeking end-to-end, cross-platform assay development and validation in immunotherapy programs.

Regulatory readiness Highlight CLIA accredited and GCLP-compliant capabilities as a differentiator for sponsors aiming to move complex biomarker assays from discovery to clinical trials, reducing regulatory risk and timeline for translational research.

High-value capabilities Target mid to late-stage biotech and biopharma firms focusing on tumor microenvironment and spatial biology to offer scalable, high-plex panel design (up to 40 markers) and ultradeep immune profiling to accelerate biomarker discovery and patient stratification.

Global growth signals Capitalize on a growing revenue trajectory and a lean team to propose agile, cost-efficient collaborations with mid-sized companies seeking CROs that can bridge technology gaps and accelerate development timelines without large enterprise overhead.